Compare DexCom, Inc. (DXCM) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs UnitedHealth Group Inc — how do they compare? DexCom, Inc. trades at $84.08 (market cap $31.86B), while UnitedHealth Group Inc trades at $379.1 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 10.5× DexCom, Inc.'s market cap, and UnitedHealth Group Inc pays a 2.5% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and UnitedHealth Group Inc for 97 Days on average.
| DXCM | UNH | |
|---|---|---|
Market Cap | $31.86B | $332.96B |
Volume | 3,607,070 | 7,273,749 |
Sector | Health | Health |
52-Week High | $92.34 | $436.35 |
52-Week Low | $54.84 | $259.02 |
Typical Hold Time | 62 Days | 97 Days |
Enterprise Value | $31.32B | $374.82B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
UnitedHealth Group (UNH) trades at $375.98, showing minor daily weakness but maintaining a bullish technical signal. The company reported strong Q2 2026 earnings, beating estimates, and reaffirmed its full-year outlook. Revenue growth remains robust, though net margins have compressed from prior years. Analyst sentiment is overwhelmingly positive, with a consensus price target of $473.89 implying significant upside.
The outlook for UNH is favorable, driven by earnings momentum and strategic initiatives like AI investment. Key risks include regulatory pressures and medical cost trends. The stock presents a compelling opportunity for investors seeking exposure to a leading healthcare company with solid fundamentals and Wall Street support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
